<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied clinical and biological features of five cases of hybrid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Three of the five patients were classified as biphenotypic <z:hpo ids='HP_0001909'>leukemia</z:hpo> because of the coexpression of myeloid/B lymphoid markers in patients 1 (<z:e sem="disease" ids="C0026999" disease_type="Neoplastic Process" abbrv="">FAB M2</z:e>) and 2 (FAB CMMoL) and myeloid/T lymphoid markers in patient 3 (<z:e sem="disease" ids="C0023479" disease_type="Neoplastic Process" abbrv="AMML">FAB M4</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Patient 4 was identified as bilineal-biphenotypic <z:hpo ids='HP_0001909'>leukemia</z:hpo> because <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (<z:e sem="disease" ids="C0023479" disease_type="Neoplastic Process" abbrv="AMML">FAB M4</z:e>) and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (<z:e sem="disease" ids="C0522628" disease_type="Neoplastic Process" abbrv="">FAB L1</z:e>) coexisted and each population coexpressed myeloid and T lymphoid markers </plain></SENT>
<SENT sid="3" pm="."><plain>Patient 5 was identified as bilineal <z:hpo ids='HP_0001909'>leukemia</z:hpo> due to the conversion from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (<z:e sem="disease" ids="C0026998" disease_type="Neoplastic Process" abbrv="">FAB M1</z:e>) to ALL (<z:e sem="disease" ids="C0522628" disease_type="Neoplastic Process" abbrv="">FAB L1</z:e>) at an interval of 3 months </plain></SENT>
<SENT sid="4" pm="."><plain>The Philadelphia (Ph1) chromosome was negative in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="5" pm="."><plain>A leukemic blast colony formation using cell line 5637 conditioned medium as a stimulator was obtained in <z:hpo ids='HP_0000001'>all</z:hpo> four patients examined </plain></SENT>
<SENT sid="6" pm="."><plain>Three of the five patients had been suffering from so-called stem cell disorders such as <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in patient 2, trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> in patient 4 and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation in patient 5 </plain></SENT>
<SENT sid="7" pm="."><plain>The pre-existing impairment of pluripotent stem cell was probably the background of these hybrid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Hybrid <z:hpo ids='HP_0001909'>leukemia</z:hpo> appears to have an inferior prognosis: an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-directed chemotherapy resulted in a low remission rate (2/5) with a short duration of relapse free survival (1/2) and an ALL-directed chemotherapy produced no remission (0/3) </plain></SENT>
<SENT sid="9" pm="."><plain>Chronological phenotypic analysis revealed that hybrid features of leukemic blasts disappeared at the time of relapse in patient 1 and progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in patient 2 </plain></SENT>
<SENT sid="10" pm="."><plain>Monitoring of lineage-associated markers should be required for the management of hybrid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>